Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673063 | 0.98 | HRH3 (1.00) | HRH3KCNH2CYP2D6MCHR1 | |
| SCHEMBL3668484 | 0.94 | HRH3 (0.89) | HRH3KCNH2CYP2D6MCHR1HDAC1 | |
| SCHEMBL3736462 | 0.93 | HRH3 (0.86) | HRH3KCNH2 | |
| SCHEMBL4944433 | 0.92 | HRH3 (0.89) | HRH3KCNH2CYP2D6MCHR1HDAC1 | |
| SCHEMBL3670948 | 0.91 | HRH3 (0.86) | HRH3KCNH2 | |
| SCHEMBL3725079 | 0.83 | HRH3 (1.00) | HRH3KCNH2CYP2D6MCHR1HDAC1 | |
| SCHEMBL3727978 | 0.83 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL3735236 | 0.81 | HRH3 (0.89) | HRH3KCNH2CYP2D6MCHR1HDAC1 | |
| SCHEMBL4944133 | 0.81 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL3732818 | 0.79 | HRH3 (0.67) | HRH3KCNH2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | claimed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | claimed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HRH3 2/4885KCNH2 581/4885CYP2D6 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.